Clinical Trial Update: Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase I pharmacokinetic comparison study of Vorico Injection 200mg versus Vfend IV 200mg in healthy volunteers completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aspergillus Infections
• Candida Infections
• Fungal Infections

Drugs mentioned

• Vfend 200mg IV (voriconazole)
• Vorico Injection 200mg (voriconazole)

Snippet

Sponsor: Chong Kun Dang Pharmaceutical | Conditions: Aspergillus Infections, Candida Infections | Phase 1 | Status: COMPLETED | Results posted: 2020-03-18